Stock_Titan Posted - 3 days ago

$KYMR Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update https://www.stocktitan.net/news/KYMR/kymera-therapeutics-announces-first-quarter-2024-financial-results-ort91uwxe75w.html

net0trader Posted - 3 days ago

@MaverikIT @Cash4freedom @RonIsWrong @IsabellaDC @DonCorleone77 @Wigglyick @Im_not_Mr_Lebowski love it. $KYMR is just the my kind of setup

Stock_Titan Posted - 04/25/24

$KYMR Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 https://www.stocktitan.net/news/KYMR/kymera-therapeutics-to-report-first-quarter-2024-financial-results-r3cagw1fjuze.html

MaverikIT Posted - 04/23/24

@IsabellaDC @DonCorleone77 @net0trader @RonIsWrong @Im_not_Mr_Lebowski @Cash4freedom @Wigglyick $KYMR $SWTX

Quantumup Posted - 04/22/24

Oppenheimer🏁 $KYMR OP/$53 KYMR has the pot 2 deliver 1st/best-in-indication, Tx's in inflammation/immunology thru the pursuit of validated🎯s/pathways=multi-billion $ oppys if successful. 📝KT-474(IRAK4) P'ship w/ $SNY + $750M cash which believes will take KYMR into 2027: $arvn $pfe

Stock_Titan Posted - 04/08/24

$KYMR Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting https://www.stocktitan.net/news/KYMR/kymera-therapeutics-announces-scientific-presentations-at-the-d2gspss53lb2.html

WallStJesus Posted - 1 month ago

$KYMR BAKER BROS STAKE

DailyStocksPicks Posted - 03/27/24

My Oversold pick #1 for today is $NMRA It's seen as a clinical-stage biopharmaceutical company focusing on brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Despite reporting significant losses, analysts hold a positive outlook, suggesting a strong potential upside based on its clinical pipeline​​​​. $KYMR, $CGON, $RXRX, $DNA https://youtu.be/7pOcCYEQIxM

G101SPM Posted - 03/27/24

#SHOWTIME March 28, 2024 $KYMR, $PTGX, $VYNE H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference.

Stu512 Posted - 03/26/24

$KYMR Ahhh @ejz92…..did someone offend you ??? ahhh I have a nipple for your bottle !

free_stock_alerts Posted - 03/21/24

$KYMR looks good, 50 coming!

Stu512 Posted - 03/18/24

$KYMR And $60 !!! Right @MikeyNJ , lol !!! Oh ya …

Clam_Digger Posted - 03/18/24

$KYMR

MaverikIT Posted - 03/15/24

@net0trader @RonIsWrong @DonCorleone77 @Wigglyick @IsabellaDC Ron, $KYMR

insiderbuyingselling Posted - 03/13/24

$KYMR new insider selling: 353357 shares. http://insiderbuyingselling.com/?t=KYMR

DonCorleone77 Posted - 03/08/24

$KYMR 4 of 4 - Kymera Therapeutics presents preclinical data for STAT6, TYK2 degrader programs ....In addition, TYK2 degradation leads to superior inhibition of the Type 1 IFN pathway compared to TAK-2791, which is relevant to the treatment of interferonopathies. The biological differentiation of the TYK2 degrader, KT-294, combined with the ability to provide deep and sustained TYK2 knockdown in vivo with low daily oral doses, has the potential to deliver a best-in-class TYK2 profile with broad activity across multiple IL-12/IL-23- and IFN-driven immune-inflammatory diseases potentially reaching pathway biologics activity. The company plans to share additional preclinical data for KT-621 and KT-294 at upcoming medical meetings in 2024.

DonCorleone77 Posted - 03/08/24

$KYMR 3 of 4 - Kymera Therapeutics presents preclinical data for STAT6, TYK2 degrader programs ....These data demonstrate the potential of KT-621 for the treatment of atopic dermatitis and other allergic diseases with best-in-pathway potential given its dupilumab-like activity profile and the convivence of an oral pill. Additionally, in preclinical studies, KT-294, Kymera's first-in-class highly selective oral TYK2 degrader, demonstrated picomolar degradation potency and potent inhibition of the IL-23, IL-12 and Type I IFN pathways, showing its potential to recapitulate the biology of human TYK2 loss-of-function profile. KT-294, does not impact any of the other Janus kinase proteins and in doing so spares IL-10, unlike the TYK2 small molecule inhibitor, deucravacitinib, which is important in inflammatory bowel disease....

DonCorleone77 Posted - 03/08/24

$KYMR 2 of 4 - Kymera Therapeutics presents preclinical data for STAT6, TYK2 degrader programs ...Data from both Phase 1 trials are expected to be reported in 2025. The findings presented today demonstrate that in preclinical studies, KT-621, Kymera's first-in-class oral STAT6 degrader, was exquisitely selective for STAT6 over other STATs and fully blocked IL-4/IL-13 functions in key human TH2 cellular assays with picomolar potency that was superior to dupilumab. At low daily oral doses, preclinical studies with KT-621 demonstrated near full in vivo STAT6 degradation in disease-relevant tissues that was well-tolerated. In a MC903-induced atopic dermatitis mouse model, KT-621 demonstrated robust degradation of STAT6 in spleen and marked reduction of total serum IgE comparable to the activity of dupilumab....

DonCorleone77 Posted - 03/08/24

$KYMR 1 of 4 - Kymera Therapeutics presents preclinical data for STAT6, TYK2 degrader programs Kymera Therapeutics announced that its preclinical data demonstrating the therapeutic potential of its potent and selective heterobifunctional degraders of STAT6 and TYK2 are being presented in the poster session at the American Academy of Dermatology's Annual Meeting in San Diego, California. Kymera's oral STAT6 and TYK2 degraders have the potential to address multiple immune-mediated diseases and overcome the limitations of existing technologies and agents. Today's poster presentations mark the first time that data from a STAT6 targeted agent and a TYK2 degrader have been shared at a major medical meeting. Based on the results generated to date, Kymera intends to initiate Phase 1 testing for KT-621 and KT-294 in the in the second half of 2024 and the first half of 2025, respectively....

Stock_Titan Posted - 03/08/24

$KYMR Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting https://www.stocktitan.net/news/KYMR/kymera-therapeutics-presents-preclinical-data-for-stat6-and-tyk2-hk1zwyhlrggn.html

Stu512 Posted - 03/08/24

$AGIO Reason this grabs only 1.7B MC….is because it is loaded with the biotech rejects. $RYTM and $KYMR , still have credible Senior execs running the show, either the founder or a god father of Biotech ( David Meeker) ..here , it is unemployed ex biotech entourage. Others with no drug , lol are at 2.5B MC ….proof is beholding

MikeyNJ Posted - 2 months ago

$KYMR Just read the UBS research report dated February 23. Very compelling. Analyst maintains $80 price target with high conviction.

Stu512 Posted - 2 months ago

$KYMR finally , all the subscribers to the offering are out, and now short !! they flipped it and went short !!! As I stated would happen

Clam_Digger Posted - 2 months ago

$KYMR Buying opportunity, $54 PT.

Stu512 Posted - 2 months ago

$KYMR $60 right !!! With Phase 2a hardly enrolled, yah. I have a gold mine to sell you, it is 20,000 Leagues under the SEA.

Clam_Digger Posted - 2 months ago

$KYMR 🤑🤑🤑🤑🤑

MikeyNJ Posted - 2 months ago

$KYMR Truist Securities raises price target to $54 from $41.

Stu512 Posted - 02/29/24

$KYMR Hmmmm that $60 still hasn’t arrived….well it was promo time here ( for cash) and over at $AGIO for a director to cash in some options !! ( that director failed as a CEO and COB, to create value , thus employed and paid Morgan Stanley to pump the stock for his options that he could cash in. lol….) most CEO’s create value and merely sell shares , NOT SCHENKIEN, he needed help , hahaha.